Clinical Trial Technology Trends For BioPharma And CROs

By Rod McGlashing, Data Science Subject Matter Expert and Melissa Newara, VP of eClinical Solutions and Consulting

The adoption of eClinical technologies by small biopharma organizations and CROs is on the rise. In a survey of 150 people, conducted by BioPharma Dive studioID, results found that 98% of clinical studies now utilize multiple eClinical tools. Technologies such as eConsent, EDC, and eTMF are of particular use in early-phase trials (Phase I and II) and early integration has shown significant benefits in data completeness, accuracy, and supply chain management. High-quality data is critical for regulatory approval, and the survey respondents cited increased data quality, reduced cycle times, and lower labor costs as key advantages of eClinical technologies.

While there is strong confidence in current eClinical platforms, there are concerns about their ability to manage future complexities such as synthetic control arms and decentralized trials. The pandemic has demonstrated the industry's adaptability, bolstering confidence in the continued evolution of eClinical tools. Explore the ways the industry is still grappling with the implications of emerging methodologies and the prioritization of efficiency-related factors in clinical trials.